Lab test for a new Merkel cell cancer treatment
Part of Cancer, Immune system & allergy, Skin clinical trials.
This trial is testing a lab method to see if a specific type of immunotherapy can work against Merkel cell carcinoma. It may help find new treatment options for people with this skin cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with Merkel cell carcinoma of the skin
- You are currently receiving or have recently completed treatment for your cancer, or are being monitored for it
- You are not taking part in any other clinical trial at the same time
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people with Merkel cell carcinoma take part in clinical trials. It helps researchers understand what helps or makes it hard for patients to join and stay in studies.
This study looks for Merkel cell carcinoma cells in the blood before and after surgery (and/or radiation). It may help researchers understand how these cells change with treatment.
This trial tests an experimental vaccine (IFx-Hu2.0) followed by the immunotherapy drug pembrolizumab in people with advanced Merkel cell carcinoma who have not been treated with checkpoint inhibitors before. The goal is to see if this combination helps shrink or control the cancer.
This study looks at how insurance covers immunotherapy given before surgery for certain skin cancers. It includes people with Merkel cell, mucosal melanoma, basal cell, or other rare skin cancers who are planning to have surgery.
This trial tests a combination of two immunotherapy drugs, nivolumab and relatlimab, before surgery for Merkel cell carcinoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests the combination of pembrolizumab (an immunotherapy) with standard chemotherapy (cisplatin or carboplatin plus etoposide) in people with advanced Merkel cell carcinoma who haven't had treatment before. The goal is to see if this combination improves outcomes.
Hear when a new Merkel Cell Carcinoma of Skin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.